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Introduction 1 
Ciguatera is a perplexing neurological disease caused by consumption of highly lipophilic 2 
polyether compounds known as ciguatoxins (CTX) that bioaccumulate in tropical and sub-3 
tropical fish. Clinically, ciguatera is associated with gastrointestinal disturbances of limited 4 
duration, in particular nausea, diarrhoea and abdominal pain, with neurological disturbances 5 
being the predominant presentation. The neurological symptoms of ciguatera include 6 
distressing, often persistent sensory disturbances such as perioral and distal paraesthesias, 7 
dysaesthesias, pruritus, headache and asthenia [18; 21]. Of these neurological disturbances, 8 
temperature dysaesthesia, or cold allodynia, is considered pathognomonic and occurs in up to 9 
95% of ciguatera victims [3; 21].  10 
At the molecular level, ciguatoxin is the most potent known activator of voltage-gated 11 
sodium channels (Nav) [23]. Ciguatoxin also inhibits neuronal potassium channels [5], 12 
resulting in further increased neuronal excitability. The pharmacological action of 13 
ciguatoxins on Nav in excitable cells results in a range of pathophysiological effects, 14 
including spontaneous action potential discharge, release of neurotransmitters, increase of 15 
intracellular Ca2+, and axonal Schwann cell oedema (for review see [27]). 16 
Importantly, clinical management of the peripheral sensory disturbances associated with 17 
ciguatera, in particular cold allodynia, remains symptomatic and relies on the largely empiric 18 
choice of analgesics. This reflects both difficulties in recruiting ciguatera patients in 19 
sufficient numbers for systematic randomised controlled trials, as well as the absence of 20 
suitable in vitro and in vivo models able to assess the therapeutic potential of various 21 
compounds. We thus sought to establish a novel in vitro ciguatoxin assay to identify 22 
inhibitors of acute ciguatoxin-induced Nav activation at the cellular level. In addition, we 23 
systematically evaluated the anti-allodynic effects of approved analgesic drugs and 24 
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medications modulating neuronal excitability in a novel animal model of ciguatoxin-induced 1 
cold allodynia with the aim to identify new treatment strategies for this painful condition.  2 
 3 
Materials and Methods 4 
Materials 5 
P-CTX-1, P-CTX-2 and P-CTX-3 were isolated from the viscera of moray eel and purified as 6 
previously described [11]. Brevetoxin-A (BTX-A) was obtained from Latoxan (France). 7 
Synthetic conopeptides CVID (Cav2.2 inhibitor), TIIIA (Nav1.2/Nav1.1 inhibitor) and GIIIA 8 
(Nav1.1/Nav1.6 inhibitor) were a kind gift from Prof. Paul Alewood, Institute for Molecular 9 
Bioscience, The University of Queensland. Veratridine was obtained from Ascent Scientific 10 
(Bristol, UK), tetrodotoxin (TTX) was from Enzo Life Sciences (Farmingdale, NY, USA) 11 
and ProTxII was from Peptides International (Louisville, KY, USA). All other reagents, 12 
unless otherwise stated, were obtained from Sigma Aldrich (Castle Hill, NSW, Australia). P-13 
CTX-1. P-CTX-2, BTX-A, ProTxII, and TIIIA were routinely diluted in 0.3–0.5 % bovine 14 
serum albumin (BSA) solution to avoid adsorption to plastic surfaces. 15 
 16 
Ethics approval for human experiments 17 
The local human ethics committee of the University of Erlangen approved human studies that 18 
were conducted in accordance with German law, the Declaration of Helsinki principles and 19 
the Belmont Report. The dose of Pacific Ciguatoxin-1 (P-CTX-1) administered by shallow 20 
intracutaneous injection (0.2-2 pg/kg) was extrapolated from the minimum pathogenic oral 21 
dose (0.6 ng/kg)[2]. Independent academic volunteers (n=5) were recruited and a detailed risk 22 
assessment and information sheet was provided to all participants. Informed written consent 23 
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was obtained prior to the experiment. All participants gave their consent voluntarily and 1 
could have withdrawn from the study at any time. 2 
 3 
Assessment of ciguatoxin-evoked effects in human volunteers 4 
P-CTX-1 was isolated from moray eel and purified to > 95% purity by HPLC using good 5 
laboratory practice [11]. The lyophilized non-pyrogenic material was reconstituted in sterile 6 
medical grade Ringer solution for intradermal injection. For injections, P-CTX-1 was 7 
prepared as 0.1 nM – 10 nM solution in sterile Ringer’s solution and injected 8 
intracutaneously in a volume of 50 μl into the volar forearm of study participants (age 27-50). 9 
Thermal sensitivity was assessed by exposure of the injection site to a surface cooled using a 10 
vortex thermode [4] with temperatures ranging from 40 – 2 °C at a rate 0.5 °C/s. Pain 11 
sensations were rated verbally by the subjects (n = 5) in 2 °C intervals on a 11 point scale in 12 
which 0 is no pain, 3 pain threshold and 10 maximal imaginable pain. The ciguatoxin-13 
induced axon reflex sweating was measured as previously described [14] using a custom-14 
made sweat chamber, in which moisture accumulation of dry air passed over the skin was 15 
quantified using a humidity sensor (HygroClip-SC04, Rotronic GmbH, Germany). Sweat 16 
output is presented in mV from data recorded by the humidity sensor control unit (HygroLab 17 
2, Rotronic GmbH, Germany). The ciguatoxin-induced neurogenic flare reaction was 18 
quantified using a Laser Doppler Imager (LDI; Moore, London, UK) as previously described 19 
[14]. Briefly, a rectangular area (158 x 102 pixels or 75cm²) surrounding the P-CTX-1 20 
injection site was scanned with a spatial resolution of 0·5 mm from a distance of 35 cm at 21 
baseline and at 2 minute intervals.  22 
 23 
CGRP release 24 
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Male Wistar rats weighing 60-80 g were sacrificed by exposure to 100% CO2 and the skin 1 
covering both hindpaws was isolated through subcutaneous excision, sparing the toes, larger 2 
vessels and saphenous and peroneal nerve stems. The resulting skin flaps (0.13-0.35 g) were 3 
secured to acrylic rods and tied in place, corium side exposed. After equilibration for 30 min 4 
in 32 °C synthetic artificial fluid (SIF; composition: NaCl 108 mM, NaHCO3 26·2 mM, 5 
sodium gluconate 9·64 mM, glucose 5·55 mM, sucrose 7·6 mM, KCl 3·48 mM, NaH2PO4 6 
1·67 mM, CaCl2 1·53 mM and MgSO4 0·69 mM, pH 7·3) gassed with carbogen, the flaps 7 
were placed in glass vessels containing varying concentrations of P-CTX-1 and incubated for 8 
5 min in a shaking bath at 32 °C. The CGRP content was determined as previously described 9 
in detail using a commercial enzyme immunoassay kit (SPIbio, Montigny, France) and a 10 
microplate reader (Dynatech, Channel Islands, UK) [1; 29]. 11 
 12 
In vitro ciguatoxin assay in SH-SY5Y cells 13 
SH-SY5Y human neuroblastoma cells were routinely maintained in RPMI medium 14 
(Invitrogen, Australia) supplemented with 15 % foetal bovine serum and L-glutamine [18].  15 
To assess responses elicited by activation of endogenously expressed Nav1.2, Nav1.3 and 16 
Nav1.7, cells were plated on 384-well black-walled imaging plates (Corning) 48 h prior to 17 
loading with Calcium-4 dye (Molecular Devices, Sunnyvale, CA) for 30 min at 37 ˚C. 18 
Fluorescence responses (excitation 470–495 nm; emission 515–575 nm) to addition of P-19 
CTX-1, P-CTX-2, P-CTX-3 or BTX-A were assessed using a FLIPRTETRA plate reader 20 
(Molecular Devices). Raw fluorescence readings were converted to response over baseline 21 
using the analysis tool of Screenworks 3.1.1.4 (Molecular Devices) and were expressed 22 
relative to the maximum increase in fluorescence of control responses. 23 
 24 
Ciguatoxin-induced cold allodynia 25 
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The University of Queensland Animal Ethics Committee approved experiments involving 1 
animals. Cold allodynia was assessed in adult male C57BL/6 mice as described [26]. Nav1.3-/- 2 
animals were a kind gift from Prof John Wood (University College, London) and were back-3 
crossed on C57/BL6 background for at least 6 generations. P-CTX-1 (5 nM), P-CTX-3 (15 4 
nM), BTX-A (300 nM) and veratridine (50 µM) were diluted in sterile saline containing 0.3% 5 
serum albumin and administered in a volume of 40 µl by shallow intraplantar (i.pl.) injection 6 
under brief isoflurane (3%) anaesthesia. Drugs were administered in a volume of 500 µl by 7 
intraperitoneal injection 60 min prior to assessment of cold allodynia. To assess cold 8 
allodynia, the number of paw lifts, licks or shakes when exposed to a temperature-controlled 9 
(15 °C) Peltier plate (Ugo Basile, Comerio, Italy) was counted by a blinded investigator for 5 10 
min.  11 
 12 
Motor performance assessment 13 
To assess the effect of drugs on motor performance, locomotor activity was assessed using a 14 
standard Rotarod test. In brief, 7 days prior to the test, animals were trained in 5 separate 15 
sessions to walk on a rotating drum (Rotarod, Ugo Basile, Italy), with the speed increasing 16 
gradually over 5 min from 8 to 40 rpm. On the day of the test, analgesic drugs were 17 
administered 60 min prior to the motor performance test, and the latency to fall was recorded 18 
by a blinded observer at 24 rpm with a cut-off of 5 min. The change in the latency to fall was 19 
determined for each animal respective to its pre-treatment performance. 20 
 21 
Activity at heterologously expressed Nav isoforms 22 
Nav responses were assessed in Chinese Hamster Ovary (CHO) cells heterologously 23 
expressing hNav1.3, hNav1.6, hNav1.7 and hNav1.8 (Chantest, Cleveland, Ohio) as previously 24 
described [24]. Cells were plated 24-48 h prior to the assay on 384-well black-walled 25 
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imaging plates at a density of 10,000-15,000  cells/well and were loaded with red membrane 1 
potential dye (Molecular Devices) according to the manufacturer’s instructions for 30 min at 2 
37 °C. Changes in membrane potential after pre-treatment with varying concentrations of 3 
small molecule Nav inhibitors were assessed using the FLIPRTetra (excitation 515-545 nm, 4 
emission 565-625 nm). 5 
 6 
Data analysis and statistics  7 
Data was plotted and analyzed using GraphPad Prism Version 4.00. Statistical significance 8 
was defined as p < 0.05 and was determined using One-way ANOVA analysis with Dunnett’s 9 
post-test.  10 
 11 
Results 12 
Peripheral administration of P-CTX-1 elicits sensory disturbances consistent with the clinical 13 
symptomatology of ciguatera 14 
Intracutaneous injections of P-CTX-1 into the volar forearm of human volunteers caused 15 
dose-dependent, strictly localized peripheral sensory disturbances consistent with the clinical 16 
symptomatology of ciguatera that were associated with a marked axon reflex flare and axon 17 
reflex sweating (Fig. 1A-E). Sub-nanomolar (0.1 nM) concentrations of P-CTX-1 elicited 18 
localized pruritus, while at higher concentrations (1 nM) intense, short-lasting burning pain 19 
and cold allodynia were experienced. The symptoms of cold allodynia persisted for several 20 
hours, with exposure of the ciguatoxin-injected region of the forearm to innocuous cool 21 
temperatures eliciting intense stabbing, pricking and burning pain (Fig. 1F) that was relieved 22 
immediately upon warming. The axon reflex erythema is generally caused by release of the 23 
vasodilatory neuropeptide calcitonin gene-related peptide (CGRP) from axons and nerve 24 
terminals [20]. Quantification of CGRP release from rat skin illustrated the exquisite potency 25 
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of P-CTX-1 to activate cutaneous nerve endings (Fig. 1G).  In contrast, neither detectable 1 
prostaglandins nor histamine were released by P-CTX-1 up to 10 nM (data not shown), which 2 
supports a direct and specific action of P-CTX-1 on nociceptors and sympathetic fibers at low 3 
nM concentrations. These findings are consistent with previous reports of preferential 4 
activation of peptidergic, CGRP-positive sensory neurons by P-CTX-1, but little effect of 5 
ciguatoxins on IB4-positive neurons [26]. 6 
 7 
A novel assay for in vitro characterization of ciguatoxin-induced responses 8 
Clinical management of ciguatoxin-induced sensory neuropathies currently relies largely on 9 
symptomatic treatment based on the empiric choice of analgesic compounds. However, little 10 
is known about the in vitro and in vivo efficacy of clinically available analgesics for treatment 11 
of ciguatera. To assess the ability of clinically available Nav and potassium channel 12 
modulators to inhibit acute ciguatoxin-induced responses, we established a novel in vitro 13 
ciguatoxin assay in the human neuroblastoma cell line SH-SY5Y. These cells endogenously 14 
express Nav channels relevant for pain signalling, including Nav1.2, Nav1.3 and Nav1.7, and 15 
are thus a suitable model for assessment of in vitro efficacy of Nav inhibitors with analgesic 16 
effect [25].  17 
 18 
Consistent with the site 2 toxin veratridine eliciting Ca2+ responses in SH-SY5Y cells through 19 
activation of Nav, which in turn leads to activation of endogenously expressed Cav channels 20 
and influx of Ca2+, the site 5 toxins P-CTX-1, P-CTX-2, P-CTX-3 and BTX-A were able to 21 
elicit concentration-dependent Ca2+ responses with an EC50 of 2.2 ± 0.6 nM, 9.3 ± 2.6 nM, 22 
8.3 ± 2.4 nM and 160.7 ± 19.3 nM, respectively (Fig. 2A). The ciguatoxin-induced responses 23 
were completely inhibited in the presence of 300 nM TTX (Fig. 2B and C). Similar to 24 
veratridine-induced responses [18], P-CTX-1 responses were partially inhibited by nifedipine 25 
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(75.5 ± 4.3 % inhibition) and CVID (36.3 ± 3.6 % inhibition; Fig. 2D), consistent with 1 
contribution of both L- and N-type channels to Ca2+ responses elicited by P-CTX-1. 2 
Surprisingly, Nav1.7 did not contribute substantially to P-CTX-1 responses, as ProTxII 3 
blocked responses with an IC50 of 4.3 ± 3.1 µM (pIC50 6.45 ± 0.65) and inhibited only 11.9 ± 4 
1.6 % of responses at a concentration (100 nM) that fully inhibits Nav1.7 (Fig. 2C). In 5 
addition, the Nav1.2-selective conopeptide TIIIA inhibited 25.4 ± 0.9 % of responses (pIC50 6 
7.23 ± 0.19; Fig 2C), suggesting that the majority of P-CTX-1-induced Ca2+ influx in SH-7 
SY5Y cells is mediated through Nav1.3, the third sodium channel subtype present in these 8 
cells. 9 
Using this assay, we characterised the ability of clinically used analgesic compounds to 10 
inhibit P-CTX-1 responses. Consistent with their reported pharmacological effects on Nav 11 
and Kv channels, all compounds tested, with the exception of topiramate, were able to 12 
concentration-dependently inhibit ciguatoxin-induced responses (Fig. 3A). Amitriptyline was 13 
most potent (pIC50 4.91 ± 0.22), while lamotrigine (pIC50 3.03 ± 0.05) and phenytoin (pIC50 14 
3.52 ± 0.57) were less potent than flupirtine (pIC50 4.00 ± 0.25), mexiletine (pIC50 3.99 ± 15 
0.27) and carbamazepine (pIC50 4.19 ± 0.51) (Fig. 3B).  16 
 17 
In order to assess the therapeutic potential of these compounds, we assessed their analgesic 18 
efficacy in a novel animal model of ciguatoxin-induced cold allodynia. Intraplantar 19 
administration of P-CTX-1 induces cold allodynia [26], consistent with the clinical 20 
presentation of ciguatera and our findings from intradermal injection of P-CTX-1 in human 21 
volunteers (Fig 1). As expected, intraplantar injection of an equivalent concentration of P-22 
CTX-3, based on its in vitro potency in SH-SY5Y cells, also elicited cold allodynia (Fig. 4A). 23 
However, intraplantar injection of the site 5 toxin BTX-A, or the Nav activator veratridine, 24 
surprisingly only elicited spontaneous nocifensive behaviour (data not shown) but no cold 25 
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allodynia (Fig. 4A). This finding supports the relevance of our animal model to the clinical 1 
presentation of ciguatera, and validates cold allodynia as a hallmark feature of the effects of 2 
ciguatoxins on peripheral sensory neurons. 3 
 4 
Analgesic treatment of ciguatoxin-induced cold allodynia 5 
Based on these results, we used our novel animal model of ciguatoxin-induced peripheral 6 
sensory disturbances [26] to assess the analgesic effect of these compounds tested at doses 7 
approximately equivalent to ceiling doses used in humans. Surprisingly, only lamotrigine (10 8 
mg/kg; 82.5 ± 6.1 % inhibition), flupirtine (10 mg/kg, 72.0 ± 5.0 % inhibition) and phenytoin 9 
(10 mg/kg; 57.5 ± 6.3 % inhibition) significantly (p < 0.05) reduced ciguatoxin-induced cold 10 
allodynia, while amitriptyline (3 mg/kg; 2.5 ± 13.2 % inhibition), carbamazepine (10 mg/kg; 11 
34.9 ± 3.0 % inhibition), topiramate (50 mg/kg; 24.7 ± 14.1 % inhibition) and mexiletine (10 12 
mg/kg; 30.7 ± 12.4 % inhibition) had no significant effect on ciguatoxin-induced cold 13 
allodynia (Fig. 4B). The observed effects on cold allodynia were not due to impaired motor 14 
performance, since only amitriptyline caused a significant (p < 0.05) decrease in locomotor 15 
activity attributable to sedating effects that were apparent at the administered dose (Fig. 4C). 16 
In addition, we assessed the effect of the two most efficacious compounds, lamotrigine and 17 
flupirtine, on CGRP release. Only flupirtine (50 µM; 36.3 ± 5.3 pg/ml; control, 56.6 ± 4.6 18 
pg/ml), but not lamotrigine (50 µM; 38.5 ± 6.7 pg/ml; control, 48.3 ± 9.9 pg/ml) significantly 19 
(p < 0.05) decreased CGRP release induced by P-CTX-1 (3 nM), suggesting contribution of 20 
non-peptidergic nociceptors to ciguatoxin-induced cold allodynia, and/or central analgesic 21 
effects of these compounds. 22 
TTX-sensitive Nav isoforms contributing to ciguatoxin-induced cold allodynia 23 
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We have previously demonstrated that cold allodynia induced by local intraplantar injection 1 
of P-CTX-1 is mediated partially through Nav1.8 [26]. However, TTX-sensitive channels, 2 
expressed on unmyelinated C- as well as myelinated A-fibers, also contribute significantly to 3 
cold-induced pain after local injection of ciguatoxin [26].  To assess the contribution of TTX-4 
sensitive Nav isoforms to ciguatoxin-induced cold allodynia in vivo, we assessed the effect of 5 
subtype-selective Nav inhibitors on cold pain behaviours. Intraplantar injection of ProTxII (30 6 
nM), a Nav1.7-selective inhibitor, did not affect the development of ciguatoxin-induced cold 7 
allodynia (Fig. 5). Intraplantar administration of the Nav1.2/Nav1.1 inhibitor TIIIA (10 µM) 8 
[28] also did not affect cold allodynia, while pain behaviour was virtually abolished by 9 
concomitant intraplantar injection of A803467 (10 µM), a Nav1.8 inhibitor, and the conotoxin 10 
GIIIA (10 µM), which inhibits Nav1.4, Nav1.1, Nav1.6 and Nav1.2, but not Nav1.7 or Nav1.3 11 
[28]. In addition, ciguatoxin-induced cold allodynia and spontaneous pain was not 12 
significantly decreased in Nav1.3–/– animals (98.5 ± 13.5 % of control). This provides further 13 
evidence that TTX-sensitive isoforms other than Nav1.7 or Nav1.3 contribute to ciguatoxin-14 
induced cold allodynia, and suggests an important role for Nav1.6 in peripheral cold pain 15 
pathways [8]. However, given the lack of subtype-selective inhibitors for these isoforms, and 16 
the profound effect on motor performance in mice with loss of function mutations of Scn8a 17 
and Scn1a, the precise role of these Nav subtypes in pain pathways remains to be elucidated.  18 
 19 
We next assessed the in vitro activity of adjuvant analgesics at heterologously expressed 20 
Nav1.3, Nav1.6, Nav1.7 or Nav1.8 (Fig. 6). The rank order of inhibition was similar to that 21 
observed in SH-SY5Y cells, with amitriptyline being most potent at all Nav subtypes (pIC50 22 
Nav1.3, 4.85 ± 0.09; Nav1.6, 4.89 ± 0.17;  Nav1.7, 4.85 ± 0.11; Nav1.8, 4.51 ± 0.06), followed 23 
by flupirtine (pIC50 Nav1.3, 3.88 ± 0.18; Nav1.6, 3.86 ± 0.21;  Nav1.7, 3.99 ± 0.35; Nav1.8, 24 
3.53 ± 0.10) and mexiletine (pIC50 Nav1.3, 3.73 ± 0.08; Nav1.6, 3.65 ± 0.26;  Nav1.7, 3.93 ± 25 
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0.16; Nav1.8, 3.60 ± 0.52). Carbamazepine (pIC50 Nav1.3, 3.26 ± 0.13; Nav1.6, 3.29 ± 0.15;  1 
Nav1.7, 3.49 ± 0.17; Nav1.8, 3.45 ± 0.16), lamotrigine (pIC50 Nav1.3, 3.37 ± 0.32; Nav1.6, 2 
3.41 ± 0.39;  Nav1.7, 3.36 ± 0.10; Nav1.8, 2.87 ± 0.19) and phenytoin (pIC50 Nav1.3, 2.66 ± 3 
0.14; Nav1.6, 2.84 ± 0.13;  Nav1.7, 2.73 ± 0.12; Nav1.8, 3.06 ± 0.25) were least potent. 4 
Overall, little subtype-selectivity for Nav isoforms was apparent, suggesting that in addition 5 
to inhibition of Nav in peripheral sensory neurons, alternative mechanisms such as activity at 6 
thermosensitive TRP or neuronal potassium channels, but also central analgesic effects, may 7 
contribute to the observed anti-allodynic effects. 8 
 9 
Discussion 10 
Ciguatera, the most common non-bacterial ichthyosarcotoxism, remains a significant clinical 11 
challenge, with the treatment standard, mannitol (IV, 0.5–1.0 g/kg), no longer recommended 12 
due to a reported lack of efficacy, especially in more prevalent milder forms of the disease 13 
[10; 21]. Thus, in the absence of effective treatment strategies validated through appropriate 14 
clinical trials, management of the neurological symptoms of ciguatera, including a number of 15 
painful neuropathies, remains predominantly symptomatic. The sensory neuropathies 16 
associated with ciguatera have been postulated to arise from a direct excitatory action of the 17 
toxin on peripheral sensory neurons. However, given the presence of centrally-mediated 18 
symptoms such as ataxia in human ciguatera patients, altered central processing could also 19 
contribute to the perception of pain and cold allodynia [18]. To address this issue, we have 20 
now shown for the first time that local intradermal administration of P-CTX-1 in humans 21 
elicits symptoms consistent with ciguatera, confirming a peripheral origin of cold allodynia.  22 
To initially profile analgesics that might reverse ciguatoxin-induced activation of neurons, we 23 
established a novel ciguatoxin assay in the human neuroblastoma cell line SH-SY5Y.  In SH-24 
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SY5Y cells, ciguatoxin-induced Ca2+ responses are elicited as a result of membrane 1 
depolarisation which in turn activates Cav channels. In peripheral sensory neurons, this effect 2 
is amplified by cold-induced activation of TRPA1 in CTX-sensitive neurons, although P-3 
CTX-1 does not directly activate or potentiate TRPA1 [26]. P-CTX-1 also causes de novo 4 
Ca2+ responses to cold in cultured sensory neurons [26] , and elicits Ca2+ increases in neurons 5 
as a result of Nav-mediated membrane depolarisation (for review see [27]). Thus, neuronal 6 
cells that permit characterisation of the effects of CTX on Nav channels, in particular TTX-7 
sensitive Nav, provide an elementary in vitro model of the cellular mechanisms underlying 8 
ciguatoxin-induced neuronal activation. SH-SY5Y cells express TTX-sensitive Nav which 9 
have previously been suggested to be important in pain signalling, including Nav1.3 and 10 
Nav1.7, and were particularly sensitive to the effects of P-CTX-1 compared to other neuronal 11 
cell lines including ND7/23 and Neuro2a cells (data not shown).  Activation of endogenously 12 
expressed Nav1.2, Nav1.3 and Nav1.7 in SH-SY5Y cells leads to membrane depolarization, 13 
and subsequent Ca2+ influx through endogenously expressed voltage-gated Ca2+ channels. 14 
Thus, this assay provides an excellent signal-to-noise ratio and enables characterization of the 15 
effects of subtype-selective pharmacological modulators as well as clinically used analgesics 16 
on ciguatoxin-induced responses. Surprisingly, Nav1.2 and Nav1.7 contributed little to 17 
responses elicited by P-CTX-1, while these Nav isoforms were recently shown to mediate the 18 
majority of veratridine-induced responses in this cell line. The lack of subtype-specific 19 
Nav1.3 inhibitors prohibited direct characterization of the contribution of Nav1.3 to 20 
ciguatoxin-induced responses. However, given that responses elicited by P-CTX-1 were 21 
entirely TTX-sensitive in this cell line, and both selective Nav1.2 and Nav1.7 inhibitors 22 
blocked only a minor portion of ciguatoxin responses in SH-SY5Y cells, it seems likely that 23 
Nav1.3 is the major mediator of P-CTX-1 responses in this assay. The toxicological target of 24 
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CTX is thus distinct from veratridine, which induces Ca2+ responses in SH-SY5Y cells 1 
through activation of Nav1.2 and Nav1.7 [25].  2 
Based on their ability to pharmacologically antagonise the effects of ciguatoxin, compounds 3 
with activity at Nav, such as antiepileptics or tricyclic antidepressants, would be expected to 4 
provide effective relief from ciguatera symptoms. Thus, we characterised the in vitro efficacy 5 
of a number of clinically used adjuvant analgesics on the ciguatoxin-induced responses in this 6 
assay. All compounds except topiramate were able to inhibit P-CTX-1 responses with 7 
varying potencies. While topiramate has been reported to inhibit Nav currents in rat cerebellar 8 
granule cells [30], these cells express predominantly Nav1.2 and Nav1.6 [17], suggesting that 9 
topiramate may have a preference for inhibition of Nav isoforms other than Nav1.3 [17].  10 
Consistent with a lack of effect on P-CTX-1-induced in vitro ciguatoxin-induced responses, 11 
topiramate did not decrease ciguatoxin-induced cold allodynia significantly. Similarly, 12 
amitriptyline had no effect on cold allodynia in our animal model, consistent with previous 13 
anecdotal reports that this tricyclic antidepressant was ineffective for the treatment of 14 
ciguatera-associated cold allodynia [7; 19], despite it being the most potent inhibitor of 15 
ciguatoxin-induced responses in SH-SY5Y cells. In contrast, both lamotrigine and flupirtine 16 
provided nearly complete inhibition of cold allodynia, while phenytoin partially reversed 17 
ciguatoxin-induced cold allodynia. The reason(s) for the lack of efficacy of amitriptyline, 18 
mexiletine and carbamazepine are unclear, but may involve pharmacokinetic and 19 
pharmacodynamic effects that result in insufficient local concentration at peripheral sensory 20 
neurons at the doses selected in this study, which were chosen to be approximately equipotent 21 
based on in vitro efficacy, in vivo dosing and tolerability in animals.  22 
The weak correlation between our in vitro assay and in vivo efficacy suggests that CTX-23 
induced cold allodynia might not arise simply from activation of sodium channels. We have 24 
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previously shown that ciguatoxin-induced cold allodynia is mediated by TRPA1-expressing 1 
unmyelinated C- and myelinated A-fibers despite the lack of any direct effect of CTX on 2 
TRPA1 [26]. In addition, ciguatoxin is known to affect K+ channels, some of which also have 3 
profound effects on excitability at cool temperatures [13; 16]. Thus, CTX-induced cold 4 
allodynia appears to arise from effects of CTX on both Nav and K+ channels expressed in 5 
TRPA1-expressing C fibers as well as myelinated A-fibers, with both TTX-resistant and 6 
TTX-sensitive sodium channels contributing to this effect. 7 
 8 
The most effective analgesics in our model were lamotrigine and flupirtine, both of which 9 
affect Nav and potassium channels [6; 9]. Thus, it is plausible that rather than a subtype-10 
selective effect on a particular isoform of Nav channels, the in vivo efficacy is a reflection of 11 
the combined pharmacological profile of a given compound on Nav, Kv and perhaps TRP 12 
channels relevant for signalling in pain pathways. Such effects are too complex to be 13 
replicated well in in vitro systems, and it is thus not surprising that the potency at individual 14 
Nav isoforms was a poor predictor of efficacy. In addition to inhibition of Nav and Kv 15 
isoforms in peripheral sensory neurons, central effects of adjuvant analgesics tested here may 16 
also contribute to the observed in vivo anti-allodynic effect. Thus, the in vitro ciguatoxin 17 
assay described here is a poor model for ciguatoxin-induced cold allodynia and may more 18 
accurately reflect the acute activation of neurons by ciguatoxin. The weak correlation 19 
between in vitro and in vivo efficacy highlights the complex nature of cold allodynia and 20 
native nerve terminals and supports the need for appropriate in vivo models. Nonetheless, 21 
although not directly representative of the mechanisms underlying ciguatoxin-induced cold 22 
allodynia, the in vitro ciguatoxin assay presented here may be useful for high-throughput 23 
assessment of modulators of acute ciguatoxin-induced neuronal activation. 24 
 25 
17 
 
 1 
Nav1.3, the isoform contributing to the majority of P-CTX-1-induced responses in our in vitro 2 
assay, is expressed at low levels in adult rodent DRG neurons, and its contribution to pain 3 
remains controversial [12; 15]. Consistent with low expression levels in adult rodents, we 4 
found that Nav1.3 plays a minor role in ciguatoxin-induced cold allodynia in mice, and had 5 
no effect on spontaneous pain behaviours. It is unclear whether Nav1.3 is expressed at 6 
similarly low levels in humans, or whether this isoform contributes significantly to cold 7 
allodynia, acute pain or the axon reflex flare. Alternatively, it may be possible that this 8 
isoform contributes to ciguatera symptoms other than cold allodynia and spontaneous pain, 9 
such as central nervous system disturbances. 10 
It is clear that ciguatoxin-induced cold allodynia in mice involves contribution of both Nav1.8 11 
and TTX-sensitive Nav [26]. However, ciguatoxin-induced cold allodynia was not 12 
significantly affected in Nav1.3–/– animals. Consistent with reports that IB4-negative sensory 13 
neurons, the population which we previously found to be particularly sensitive to P-CTX-1, 14 
express TTX-sensitive Nav isoforms other than Nav1.7 [22], we found that ciguatoxin-15 
induced cold allodynia was not affected by intraplantar injection of the Nav1.7-selective 16 
inhibitor ProTxII but was blocked almost completely when Nav1.8 as well as Nav1.6 were 17 
inhibited.  18 
 19 
Interestingly, other Nav activator toxins appear to target different sodium channel 20 
combinations, since local intraplantar injection of the Nav activators BTX-A and veratridine 21 
failed to induce signs of cold allodynia using a similar protocol but caused spontaneous 22 
nocifensive behaviour, evidenced by lifting, licking, shaking and flinching of the ipsilateral 23 
hind paw. These findings validate cold allodynia as a pathognomonic symptom of ciguatera, 24 
18 
 
and support the relevance of our animal model to the clinical presentation of ciguatera. Based 1 
on our findings, as well as pharmacokinetic and safety considerations, lamotrigine and 2 
flupirtine appear to have potential in the treatment of ciguatoxin-induced cold allodynia. 3 
While these findings remain to be validated clinically, this is the first systematic evaluation of 4 
clinically used analgesics for the treatment of ciguatoxin-induced cold allodynia. 5 
 6 
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Figure Legends 
Figure 1. Peripheral sensory effects of P-CTX-1 in humans. (A-D) Subcutaneous injection 
of P-CTX-1 (1 nM; 50 μl) into the volar forearm of human subjects causes an axon reflex 
flare. Arrow; P-CTX-1 injection site. (A) Photographic image of the injection site at baseline. 
(B-D) Laser doppler image of the injection site at baseline (B), 2 min (C) and 30 min (D) 
after injection of P-CTX-1. Scale bar; perfusion units. (E) Axon reflex sweating induced by 
P-CTX-1. Arrow; timepoint of P-CTX-1 injection. Sweat output is presented in mV from 
data recorded by the humidity sensor control unit (HygroLab 2, Rotronic GmbH, Germany). 
(F) Temperature-dependence of cold pain (control, prior to P-CTX-1 injection, white) and 
cold allodynia induced by P-CTX-1 (1 nM, black) in human volunteers (n=5). (G) P-CTX-1 
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increased CGRP release from rat skin with an EC50 of 2.3 nM. The intensity and nature of 
sensations elicited by intradermal injection of P-CTX-1 in human skin paralleled CGRP 
release in rat skin, with concentrations equal to and above the EC50 of ~2.3 nM for CGRP 
release causing pain and cold allodynia, while concentrations below 1 nM caused itch. 
 
Figure 2. Characterisation of ciguatoxin-induced responses in the human 
neuroblastoma cell line SH-SY5Y. (A) In SH-SY5Y cells loaded with Calcium-4 dye, 
stimulation with P-CTX-1 (EC50 2.2 ± 0.6 nM), P-CTX-2 (EC50 9.3 ± 2.6 nM), P-CTX-3 
(EC50 8.3 ± 2.4 nM) as well as BTX-A (EC50 160.7 ± 19.3 nM) caused concentration-
dependent increases in intracellular Ca2+. (B) P-CTX-1 responses were mediated through 
TTX-sensitive Nav isoforms endogenously expressed in SH-SY5Y cells, as responses were 
completely abolished in the presence of TTX (300 nM). (C) TTX completely inhibited P-
25 
 
CTX-1 responses with an IC50 of 12.9 ± 2.2 nM, while the Nav1.2 inhibitor TIIIA caused 
partial (25.4 ± 0.9 %) inhibition with an IC50 of 49.9 ± 14.9 nM. The Nav1.7 inhibitor ProTxII 
caused a small inhibition (11.9 ± 1.6 %) at concentrations (100 nM) which fully inhibit 
Nav1.7, and blocked P-CTX-1 responses with an IC50 of 4.3 ± 3.1 µM. (D) The Cav inhibitors 
nifedipine and CVID partially blocked P-CTX-1 responses with IC50s of 59.1 ± 16.4 nM and 
33.6 ± 8.8 nM, respectively. Data is presented as mean +/- SEM and is representative of 3-9 
independent experiments 
 
 
Figure 3. Inhibition of ciguatoxin-evoked responses in the human neuroblastoma cell 
line SH-SY5Y. (A) Amitriptyline, carbamazepine, flupirtine, lamotrigine, mexiletine and 
phenytoin concentration-dependently inhibited responses elicited by addition of P-CTX-1 (3 
nM), while topiramate did not affect ciguatoxin-mediated responses at concentrations up to 1 
mM. (B) The in vitro potency (pIC50) of amitriptyline (pIC50 4.91 ± 0.22), carbamazepine 
(pIC50 4.19 ± 0.51), flupirtine (pIC50 4.00 ± 0.25), lamotrigine (pIC50 3.03 ± 0.05), mexiletine 
(pIC50 3.99 ± 0.27) and phenytoin (pIC50 3.52 ± 0.57) for inhibition of CTX-mediated 
responses. Data are presented as mean ± SEM of n = 3 independent experiments. 
26 
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Figure 4. Anti-allodynic treatment of ciguatoxin-
28 
 
induced cold allodynia. (A) Intraplantar injection of P-CTX-1 and P-CTX-3, but not the Nav 
activators BTX-A or veratridine, elicits cold allodynia (B) Lamotrigine (10 mg/kg), flupirtine 
(10 mg/kg) and phenytoin (10 mg/kg) significantly decreased cold allodynia elicited by 
intraplantar injection of P-CTX-1 (5 nM), while amitriptyline (3 mg/kg), mexiletine (10 
mg/kg), carbamazepine (10 mg/kg) and topiramate (50 mg/kg) had no significant anti-
allodynic effect. Data are presented as mean ± SEM of n = 5-16 animals. (C) The anti-
allodynic effects of lamotrigine, flupirtine and phenytoin were not due to impaired locomotor 
activity, as only amitriptyline significantly (p < 0.05) affected latency to fall in a Rotarod test. 
Data are presented as mean ± SEM of n = 5 animals. Statistical significance was determined 
using ANOVA with Dunnett’s post-test; *, p <0.05; **, p < 0.01. 
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Figure 
5. Nav isoforms contributing to ciguatoxin-induced cold allodynia. Ciguatoxin-induced 
cold allodynia was not significantly inhibited in Nav1.3–/– animals, or after intraplantar 
administration of the Nav1.7-specific inhibitor ProTxII (10 nM) and the Nav1.2/Nav1.1 
inhibitor TIIIA (10 µM). Co-administration of TIIIA (10 µM) and the Nav1.8-inhibitor 
A803467 (10 µM) partially decreased cold allodynia elicited by i.pl. administration of P-
30 
 
CTX-1. Intraplantar administration of the Nav1.1/Nav1.6 inhibitor GIIIA (10 µM) inhibited 
cold allodynia by 46.6 ± 8.9 % and was additive to inhibition of Nav1.8, with co-
administration of GIIIA and A803467 reducing cold pain behaviour by 87.2 ± 3.3 %. Data 
are presented as mean ± SEM of n = 5 – 12 animals. Statistical significance was determined 
using ANOVA with Dunnett’s post-test; *, p <0.05; ***, p < 0.001. 
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Figure 
6. Inhibition of heterologously expressed Nav isoforms by adjuvant analgesics. Inhibition 
of heterologously expressed Nav1.3, Nav1.6, Nav1.7 and Nav1.8 was assessed using a high-
throughput FLIPRTetra membrane potential assay. Amitriptyline ( ), carbamazepine ( ), 
flupirtine ( ), lamotrigine ( ), mexiletine ( ) and phenytoin ( ) concentration-dependently 
inhibited Nav1.3 (A), Nav1.6 (B), Nav1.7 (C) and Nav1.8 (D) mediated responses, while 
topiramate ( ) did not inhibit any Nav isoform assessed. (A) The in vitro potency (pIC50) for 
inhibition of heterologously expressed Nav1.3 by amitriptyline (pIC50 4.85 ± 0.09), 
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carbamazepine (pIC50 3.26 ± 0.13), flupirtine (pIC50 3.88 ± 0.18), lamotrigine (pIC50 3.37 ± 
0.32), mexiletine (pIC50 3.73 ± 0.08) and phenytoin (pIC50 2.66 ± 0.14). (B) The in vitro 
potency (pIC50) for inhibition of heterologously expressed Nav1.6 by amitriptyline (pIC50 4.89 
± 0.17), carbamazepine (pIC50 3.29 ± 0.15), flupirtine (pIC50 3.86 ± 0.21), lamotrigine (pIC50 
3.41 ± 0.39), mexiletine (pIC50 3.65 ± 0.26) and phenytoin (pIC50 2.84 ± 0.13). (C) The in 
vitro potency (pIC50) for inhibition of heterologously expressed Nav1.7 by amitriptyline 
(pIC50 4.85 ± 0.11), carbamazepine (pIC50 3.49 ± 0.17), flupirtine (pIC50 3.99 ± 0.35), 
lamotrigine (pIC50 3.36 ± 0.10), mexiletine (pIC50 3.93 ± 0.16) and phenytoin (pIC50 2.73 ± 
0.12). (D) The in vitro potency (pIC50) for inhibition of heterologously expressed Nav1.8 by 
amitriptyline (pIC50 4.51 ± 0.06), carbamazepine (pIC50 3.45 ± 0.16), flupirtine (pIC50 3.53 ± 
0.10), lamotrigine (pIC50 2.87 ± 0.19), mexiletine (pIC50 3.60 ± 0.52) and phenytoin (pIC50 
3.06 ± 0.25). Concentration-response curves are representative of 3-4 independent 
experiments, with pIC50 data presented as mean ± SEM from n = 3-4 independent 
experiments. 
 
